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ABSTRACT
 Irritable bowel syndrome (IBS) is the most common functional disorder of the gastrointestinal tract.1,2,3 As
a result of the lack of specific diagnostic testing and absence of circumscribed biology markers of the
disease, its diagnosis is based on a myriad of symptoms.1 The term irritable bowel syndrome was probably
first coined in 1944 by Peters and Bargen.4 In 1849, Cumming described the clinical manifestations of
Irritable Bowel Syndrome.1
Irritable bowel syndrome is defined on the basis of the recently modified Rome criteria as the presence of
at least 12 weeks (not necessarily consecutive) of abdominal discomfort or pain in the preceding 12 months
that cannot be explained by structural or biochemical abnormalities, and that has at least two of the
following three features: pain relieved with defecation, an onset associated with a change in the frequency
of bowel movements (diarrhea or constipation), or an onset associated with a  change in form of stool
(loose, watery, or pellet-like). The syndrome can be divided into three subcategories according to the    Modified
Rome criteria II; those with a predominant symptom of diarrhea, constipation, or constipation alternating
with diarrhea.  There are several criteria for irritable bowel syndrome, one of which is the Manning criteria,
applied in many epidemiological and clinical studies to identify irritable bowel syndrome. However, many
investigators disagree with this criteria due to a seemingly poor validity in men.4  In an attempt to bring order
to the specialty, consensus-based approach is adopted by a group of international experts, which led to the
development of the Rome criteria for irritable bowel syndrome (Table 1).4   Extra-intestinal symptoms,
including headache, backache, urinary and gynecologic symptoms, and fatigue, are more common in the
constipation-predominant subgroup.1,2,6
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EPIDEMIOLOGY
Irritable bowel syndrome is a common disorder
affecting approximately 15% of the United States
population.1,2,20 One third seek medical attention from
their primary physician, and only 1% of them are
referred to a gastroenterologist.2,6 This illness is
experienced by women three times more often than
men1,2, but in India the incident is more common in men.7
It is unclear whether this difference truly illustrates the
predomination of women or it is due to more women
seeking medical treatment.1 Menstruation is often
related to the occurrence of this illness, indicating
hormonal influence.1 Irritable bowel syndrome can
happen in all ages,2,4 but is more often found in the young
age.2,4  The elderly are more likely to have diverticular
disease.2 Studies suggest that those who seek care are
more likely to have behavioral and psychiatric problems.1, 2
PATHOPHYSIOLOGY
The pathophysiology of irritable bowel syndrome is
very complex because it is not an illness in totality. Some
aspects which are thought to be related with the
pathophysiology of totality are: change in intestinal
motility, visceral hypersensitivity, psychosocial factors,
neurotransmitter imbalance, infection,1,2,3,4,5,6 as well as
food intolerance and allergy.4,7
Altered Bowel Motility
A motility disorder is thought to be the basic problem
of irritable bowel syndrome. Some studies described
patients complaining about a feeling of incomplete rectal
emptying, solid or liquid stools, especially in patients with
constipation as a complaint.
1. Colon motility
Recto sigmoid contraction activity is lower in
diarrhea-dominant irritable bowel syndrome patients
than in control subjects. Myoelectrical colon activity
is divided into 2 types: short spike burst (SSB) in a
few seconds and long spike burst (LSB) in 30
seconds. Lower frequencies of both LSB and SSB
can be found in diarrhea-dominant irritable bowel
syndrome. LSB can be increased as well in
constipation-dominant irritable bowel syndrome.
2. Rectal motility
Balloon distension in the rectum triggers recurrent
rectum contraction in 75% of diarrhea-dominant
irritable bowel syndrome patients as well as in 50%
of control irritable bowel syndrome patients with
predominant constipation (the difference is not
significant). The volume needed to stimulate
contraction in rectum is increased in
constipation-predominant irritable bowel syndrome.
3. Intestinal bowel motility
The complex motor migration disorder of extended
contraction was reported in 61% of irritable bowel
syndrome patients and 17% in control subjects in a
study by Kellow & Philips (1987), but was not
supported by the study by Gorard et al (1994). A
group of contraction is part of intestinal bowel
contraction distributed in 1-minute durations, and is
thus also called “minute rhythm”. This contraction
Table 1. Criteria for Irritable Bowel Syndrome4 
Manning criteria (1978)* Rome II criteria (1999)† 
• Pain relieved by defecation 
 
• Looser stools at onset of pain 
• More frequent bowel movement at 
onset of pain 
• Visible abdominal distention 
• Mucus per rectum 
• Feeling of incomplete rectal 
emptying 
Pain or discomfort for 12 weeks or more in the past 12 
month associated with two of the following three: 
• Relieved with defecation 
• Association with a change in frequency of stool 
• Association with a change in form of stool 
 
Symptoms that cumulatively lend support to the 
diagnosis: 
• Abnormal stool frequency (> 3 bowel movement per 
day or < 3 bowel movement per week) 
• Abnormal stool form (lumpy/hard or loose/watery) 
• Abnormal stool passage (straining, urgency or 
feeling of incomplete rectal emptying) 
• Passage of mucus 
• Bloating or feeling of abnormal distension 
*various cutoff were applied in subsequent clinical and epidemiological studies- e.g. more than two  
asymptoms plus abdominal pain. 
† Alarm features and psychological measures are not part of the criteria 
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was more commonly found in irritable bowel
syndrome than in control subjects in the study by
Kellow & Philips (1987), but not in the other study
(Gorard et al, 1994). A shorter food transit in the
intestinal bowel causes reduced nutrient absorption,
causing increased gas production, pain and diarrhea.
Visceral Hypersensitivity
Visceral hypersensitivity is said to be the prime
component of irritable bowel syndrome.2 Balloon
distention studies of the recto sigmoid and the ileum have
shown that patients with irritable bowel syndrome
experience pain and bloating at balloon volumes and
pressures that are significantly lower than those that
induce pain in control subjects, a phenomenon referred
to as visceral hypersensitivity. One possible explanation
is that the sensitivity of receptors in the viscus is altered
through the recruitment of silent nosiceptors in response
to ischemia, distention, intra-luminal contents, infection,
or psychiatric factors.1
There may be increased excitability of the neurons in
the dorsal horn of the spinal cord, an area rich in
neurotransmitters such as catecholamine and serotonin.
Centrally, there may be differences in the way the brain
modulates afferent signals from the dorsal horn neurons
through ascending pathways. Functional magnetic
resonance imaging and positron emission tomography of
the brain show different levels of activation in the
thalamus and the anterior cingulated cortex after
balloon distention of the rectum in patients with irritable
bowel syndrome, as compared with normal subjects.
 Rectal hyperesthesia has been proven in irritable
bowel syndrome, and the severity of symptoms is
related to the degree of hypersensitivity degree. 2 In
irritable bowel syndrome, there is increased visceral
sensation but somatic perception remains normal.2 The
underlying mechanism for this phenomenon is unclear.
Balloon studies in the recto sigmoid and ileum
demonstrated that irritable bowel syndrome patients
suffered pain with a balloon volume and pressure
significantly lower than control. This phenomenon is
related to visceral hypersensitivity. One possible
explanation is that sensitivity of receptor in viscous is
changed by a nosiseptor mediator as a respond to
ischemia, distention, lumen content, infection, or a
psychosocial factor.
These findings, although controversial, suggest a primary
central defect of visceral pain processing. Some authors
have suggested that hyper-vigilance rather than true
visceral hypersensitivity may be responsible for the low pain
threshold in patients with irritable bowel syndrome.
Psychosocial Factors
Psychological stress can alter motor function in the
small bowel and colon, both in normal subjects and in
patients with irritable bowel syndrome,1 but studies of a
causal relation between irritable bowel syndrome and
physiological distress show conflicting results.19 A
cohort study of young adults in New Zealand showed
that irritable bowel syndrome was not significantly
related to an overall diagnostic history of psychiatric
illness.11  The presence or absence of a history of abuse
in childhood (sexual, physical or both) is correlated with
the severity of symptoms in patients with irritable bowel
syndrome.1,2,4 It has even been proposed that
experiences early in life may affect the central nervous
system and confer a predisposition to a state of
hyper-vigilance.1
Neurotransmitter Imbalance
Recent studies have suggested that
neurotransmitters are involved in the pathogenesis of
irritable bowel syndrome.1,2,4 Five percent of serotonin
is located in the central nervous system, and the
remaining 95 percent is in the gastrointestinal tract, within
enterochromaffin cells, neurons, mast cells, and smooth
muscle cells.1 When released by enterochromaffin cells,
serotonin stimulates extrinsic vagal afferent nerve fibers,
resulting in such physiological responses as intestinal
secretion and the peristaltic reflex and in such
symptoms as nausea, vomiting, abdominal pain and
bloating. Preliminary evidence suggests that patients with
irritable bowel syndrome have increased serotonin
levels in the plasma and in recto-sigmoid colon.
Other neurotransmitters that may have an important
role in functional gastrointestinal disorders include
calcitonin gene-related peptide, acetylcholine, substance
P, pituitary adenylate cyclase-activating polypeptide,
nitric oxide, and vasoactive intestinal peptide. These
neurotransmitters may provide links not only between
bowel contractility and visceral sensitivity, but also
between the enteric and central nervous systems.
Central processing in irritable bowel syndrome is believed
to play a strong causal role in the pathophysiology, based
on an fMRI Study.20
Infection and Inflammation
There is compelling evidence that inflammation of
the enteric mucosa or neural plexuses initiates or
contributes to symptoms associated with irritable bowel
syndrome. Mucosal inflammatory cytokines may
activate peripheral sensitization or hyper-motility. Gwee
et al. reported that in patients with infectious enteritis,
the presence of hypochondriasis and stressful life events
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at the time of the acute infection predicted the
subsequent development of irritable bowel syndrome. To
date, no single conceptual model can explain all cases of
the   syndrome.
Inflammation is associated with the production of
mediators such as prostaglandin, bradykinins, nerve
growth factors, adenosine and 5-hydroxytriptamine.
These mediators induce visceral hypersensitivity,
exaggerated motor responses, and increased intestinal
secretions, which could contribute to episodic diarrhea.4
DIAGNOSIS
The diagnosis of irritable bowel syndrome relies on
the experience and expertise of the physician, since
laboratory, radiology and endoscopies examinations are
not quite useful. An approach based on dominant
symptoms in patients is the best method. An algorithm is
used to help physicians in evaluating and treating
irritable bowel syndrome patients (Figure 1),2,5 in order
to make the cost of the treatment more effective.2 A
complete anamnesis, followed by a complete physical
examination and laboratory examination including
complete blood check, liver function check and
thyrothropine check. The diagnosis of irritable bowel
syndrome is considered if the patient’s symptoms fit the
Rome criteria. In most cases, no abnormalities are found
during physical examination or laboratory check and
there is no organic-structural problem considered as
an‘alarm symptom’.
Figure 1. Strategy for Evaluation of Subgroups of Patients with Irritable Bowel Syndrome.
      
      Manning criteria for positive diagnosis 
 
 
      Personality inventory hematology, 
      chemistry, ESR, stool for ova and parasites, 
      fecal occult blood, flexible sigmoidoscopy ±      * 
barium enema 
 
 
* Future investigation or treatment if any positive 
 
 
 
 
 
 
 
Review dietary his tory Yes Yes Yes 
Additional tests No Lactose H2 breath test  
Therapeutic trial Increase fiber 
Osmotic laxative 
Stool softener 
Loperamide 
Diphenoxylate 
Plain abdominal x-ray 
Antispasmodic  
If intractable 
consider 
Colonic transit test 
Anorectal manometry 
Jejuna aspirate for ova 
and parasites 
Small bowel x-ray 
Gastrointestinal manometry 
 Rectal sensation and 
emptying 
Pelvic floor function 
Small bowel and 
colonic transit test  
75Se HCAT test 
Balloon distention test 
 
 
*Note: the stepwise series of evaluations guided by the symptom complex (Manning’s criteria), by exclusion of organic disease, and 
by focusing on the major symptom for subsequent testing. ESR = erythrocyte sedimentation rate; 5HT = 5-hydroxytryptamine:; 
lactose H: lactose hydrogen; 75Se HCAT =  Selenium-75 homocholic acid taurine 
 
Symptom assessment 
Limeted screen for 
organic disease 
Symptom subgroup 
Constipation Diarrhea Pain/gassiness/bloating 
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If there are abnormalities on physical examination or
laboratory testing or if there are ‘alarm symptoms’,
irritable bowel syndrome is diagnosed per exclusion   after
reasonable diagnostic testing has been performed, such
as colonoscopy, computed tomography scanning of the
abdomen and pelvis, and radiographic evaluation of the
small intestines. Alarm symptoms include evidence of
gastrointestinal bleeding such as occult blood in the stool,
rectal bleeding or anemia; anorexia or weight loss;    fever;
persistent diarrhea causing dehydration; severe
constipation or fecal impaction; a family history of
gastrointestinal cancer, inflammatory bowel disease, or
celiac sprue; and the onset of symptoms at the age of at
least 50 years.   In the diagnosis of irritable bowel
syndrome, inexpensive noninvasive tests should be used
first to rule out other diagnoses.17 Colonoscopy is
indicated when a serious organic disease is reasonably
likely and needs to be ruled out.17
A number of structural or metabolic disorders that
are responsive to specific treatment cause symptoms
similar to those of irritable bowel syndrome. Lactase
deficiency is a common culprit. Other such disorders
include cancer of the colon, diverticulitis, mechanical
obstruction of the colon or small intestine, inflammatory
bowel disease, enteric infection, ischemia, maldigestion
or malabsorption, and endometriosis, suggested by the
presence of pelvic pain at the time of the menstrual
period. In the absence of alarm symptoms, the presence
of one of these structural or metabolic disorders is very
unlikely.1
MANAGEMENT APPROACH3
The aim of therapy in irritable bowel syndrome is to
achieve a rapid and sustained relief of troublesome
symptoms, to improve the person’s long-term quality of
life, and to reduce health-care-seeking behavior by
empowering the person to take control of the
requirements for and timing of therapy.3 The value of a
graded multi-component approach to the treatment of
irritable bowel syndrome has been emphasized in recent
years. One of such approach includes four levels of
potential therapy (Figure 2).3
Level 1: Explanation, Reassurance and Modifications
of Lifestyle and Behaviors
The reason for the patient’s presentation at this time
should be addressed. Fear of cancer, recent stressful
life events and the like should be explored with
appropriate sensitivity. With further questioning, the
degree to which the symptoms affect the person’s
quality of life can be ascertained. Whether the
manifestations of irritable bowel syndrome are mild,
moderate or severe will affect both the management plan
and the extent of continuing consultation. In general, the
greater the severity of irritable bowel syndrome, the
greater the impairment of quality of life.
Any obvious precipitating factors should be
identified. A careful dietary history should be taken. If
the person responds that certain foods precipitate
symptoms, a food diary may facilitate a more objective
identification of recurrent problems. The presence of
obvious stressors, such as work or family problems, should
be identified, and the relationship of these problems to
symptom exacerbations should be sought. Trials of simple
relaxation therapy can be undertaken. Therapeutic trials
of dietary modification depend on the most prominent
symptoms or on the irritable bowel syndrome subgroup.
Such trials may include supplementing the diet
according to the type of irritable bowel syndrome, with
STEP UP IBS MANAGEMENT STEP DOWN 
 Level 4: Selective gut sensorimotor modulation 
 
Level 3: Psychological approaches 
 
Level 2: Non-selective gut sensorimotor modulation 
 
Level 1: Explanation & reassurance, lifestyle & 
behavioral modification 
 
 
 
Figure 2. A four Step Approach to The Management of IBS.3 
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high fiber, and reduction in intake of lactose, fructose or
sorbitol. Reassurance of the patient is vital in the initial
management stages. There are four key areas to
address. First, the fact that the symptoms and results of
investigations positively confirm the diagnosis should be
emphasized. Second, that the disorder is a well
recognized entity, with a complex pathophysiology that
is increasingly defined. Third, despite the most
appropriate therapies, residual symptoms are likely to
recur or persist from time to time. Fourth, IBS is a
diagnosis that does not have serious or structural
complications such as diverticular disease. Available data
indicate that although patients may remain or again
become symptomatic years after a diagnosis of IBS, few
develop structural gastrointestinal disorders.
Level 2: Non-selective Gut Sensor Motor Modulation
The choice of therapy at this level depends most on
the most dominant symptom.2,3 Because symptoms of
IBS typically fluctuate, and specific drug treatments are
limited, medications should be prescribed as judiciously
as required, rather than on a regular basis.3 For
cramping abdominal pain, antispasmodics or
anticholinergics may be used if the symptoms are
moderate or severe. Although controlled clinical trials
with these agents have generally been disappointing,
meta-analyses do suggest that certain smooth muscle
relaxant can be beneficial in some cases.1,2,3,4,5 Clinical
trials have shown that antidiarrheal drugs are effective
for diarrhea, like loperamid.1,2,3,4,5 If shown to be helpful
initially, this medication can be used effectively on an
‘as needed’ basis.3
In selected cases, a trial of cholestyramine to control
possible bile salt malabsorption may be useful.1,2,3,4 For
constipation, an increase in dietary fiber and/or fiber
supplements should be continued in the longer term once
shown to be helpful.1,2,3,4 If symptoms continue, a trial of
osmotic laxatives such as magnesium-continuing salts,
lactulose or sorbitol can be tried; these medications are
safe for long term use and are often effective.1,2,3,4 A
recent placebo-controlled 16-week trial of Chinese herbal
medicines was reported, and showed that active herbal
medicines significantly improved bowel symptoms scores
and global symptoms in IBS.3,4
Level 3: Psychosocial Approaches
In moderate to severe IBS, important psychological
considerations include a firm identification of; disorders
of mood and sleep, of previous psychiatric disease, of
previous or current physical or sexual abuse, and of the
presence of chronic and highly threatening life stressors.
Where the above factors are identified, the role of
psychological treatments should be discussed. The
efficacy of psychological treatments has not been well
established;3,5 the use of these modalities has been
considered in detail recently. There is evidence that
combining multi component behavioral therapy with
medical treatment produces superior improvement in IBS
to using medical approaches alone. Low dose tricyclic
antidepressants have been used to treat the abdominal
pain of IBS. Although selective serotonin re-uptake
inhibitors are often used in IBS, randomized controlled
trials are lacking.
Level 4: Selective Gut Sensor Motor Modulation
There remains a great need for safe and effective
agents to improve the symptom cluster of IBS. These
agents should be validated in clinical trials, and targeted
at the underlying pathophysiological disturbances in IBS.
Based on recent evidence, the sensory motor
disturbances in IBS are related to disturbed
serotonergic mechanisms in the gut that act on 5HT3
and 5HT4 receptors.  Drugs like alosetron, a selective
5HT3 antagonist, are effective in treating the symptoms
of urgency, loose stool consistency and abdominal
discomfort in women with diarrhea-predominant IBS.15,16
However, this medication is being withdrawn from the
market due to the development of severe constipation
and the rare occurrence of ischemic colitis.15,16
The 5HT4 partial agonist tegaserod is well tolerated
by patients with constipation-predominant IBS in phase
three clinical trials of 16 weeks duration.14 Reported
adverse events were comparable between tegaserod and
placebo, with the exception of transient diarrhea in the
case of the active drug. The 5HT4 agonist, prucalopride,
has shown similar efficacy in phase three clinical trials in
patients with functional constipation. The clinical
availability of more effective agents than previously may
change the clinical management paradigm outlined. Thus,
by analogy with gastroesophageal reflux disease (GERD),
one may need to consider not only ‘step-up’, but also ‘
step-down’ approaches. The ‘step up’ approach
(minimum   initial therapy) would have the advantages of
avoiding over-treatment and limiting initial drug costs. The
disadvantages would be that patients may continue to
experience symptoms, and this may led to unnecessary
investigations. ‘Step-down’ therapy (higher level initial
therapy) could have the advantages of rapid symptom relief,
thereby avoiding unnecessary  investigations and
associated costs. The disadvantages would be potential
over-treatment and higher initial drug costs.
For patients in whom the disorder is manifested
predominantly as abdominal pain, a variety of
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medications have been used, and several new agents
are under development. Antispasmodic agents may
reduce abdominal pain or bloating through anticholinergic
pathways; in refractory cases, nitrates are occasionally
useful for direct relaxation of smooth muscles. Side
effects like sedation, dry mouth and eyes, and weight
gain, limit the use of primary tricyclic amines.
Secondary tricyclic amines such as anortriptyline and
desipramine may be less likely to have side effects.
Fedotozine, a kappa-opoid agonist, has shown
promise as a visceral antinociceptive agent, and other
kappa-opioid agonists are being developed. In some
patients who have abdominal pain that is refractory to
all these therapeutics agents, treatment with classic
analgesics such as no steroidal anti-inflammatory agents
(perhaps with an initial trial of a cyclooxygenase-2
inhibitor) or, in extreme cases, opioid analogues may
control the pain and improve the quality of life. The
addictive potential of opioid analogues makes them the
last choice for long-term therapy.2 In some refractory
cases, a short course of antibiotics may reduce the
diarrhea, presumably by altering the intestinal flora. The
doses of some commonly used agents are shown in (Table
2).1  Based on one study, hypnotherapy remains an
effective treatment for IBS.12
CONCLUSION
1. Irritable bowel syndrome is the most common
functional disorder in gastroenterology.
2. The pathophysiology of irritable bowel syndrome is
complex, and includes altered bowel motility, visceral
hypersensitivity, neurotransmitter imbalance,
psychosocial factors, infection, inflammation, and
food intolerance.
3. The diagnosis is based on the experience and
clinical expertise of the physician, who could refer
to the  Manning criteria or Rome II criteria.
4. A symptom-based approach is the most pragmatic
and appropriate strategy to assist the clinician to
achieve a cost effective method for diagnostic
purposes.
5. The management of the disease could be approached
in a ‘step up’ or ‘step down’ manner according to
the physician’s judgment, each with its own
advantages and disadvantages.
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